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Abstract: Dietary supplements are often used to improve the nutritional status of people 
living with HIV/AIDS (PLHIV). Arthrospira platensis (Asp), also known as Spirulina, is a 
cyanobacterium rich in proteins and micronutrients. Cell and animal trials described 
immune-modulating, antiretroviral and antioxidant activities. This pilot study describes the 
effects of the supplementation of 5 g/day of Asp on a pre-highly-active antiretroviral 
therapy (pre-HAART), HIV-infected, adult female population. It was conducted as a  
three-month randomized controlled trial (RCT) that compared a cup supplementation of 
five grams/day of Asp with a placebo of equal protein content and energy. The study 
included 73 HIV-infected women. The immediate outcome variables were CD4 T-cells, 
viral load and immune activation by CD8 T-cells expressing CD38. The antioxidant status 
was assessed by way of the total antioxidant capacity of the serum (TAOS). The renal 
function was documented by way of creatinine, urea and the calculated glomerular 
filtration rate. Statistical analyses were carried out with non-parametric tests, and the effect 
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size of each interaction was calculated. No differences in the immunological and 
virological markers between the Asp and the placebo group could be observed. In the 
placebo group, 21 of 30 patients (70%) developed concomitant events, while in the Asp 
group, only 12 of 28 patients (43%) did. Both groups registered a significant weight 
increase; 0.5 kg (p < 0.05) in the Asp group and 0.65 kg (p < 0.05) in the placebo group. 
The antioxidant capacity increase of 56 (1–98) µM for Asp was significantly different from 
the decrease observed in the placebo group (p < 0.001). A slight increase in the creatinine 
level of 0.1 g/dL (p < 0.001) was observed in the Asp group, and no effect was observed in 
the urea levels. The improvement of the antioxidant capacity under Asp, shown for the first 
time on PLHIV, could become a focus for future research on the nutritional and health 
effects of Spirulina. The observed slight, but significant increase of serum creatinine needs 
further evaluation, especially with varying doses of Asp. 
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1. Introduction 
At present, it is estimated that 34 million (range: 31.4–35.9 million) people worldwide are living 
with HIV, of whom, 23.5 (22.1–24.8) million are living in Sub-Saharan Africa [1,2]. The life 
expectancy of people living with HIV (PLHIV) has greatly improved due to the availability of  
highly-active antiretroviral therapy (HAART) [3]. However, only 36% of people in need of treatment 
in Sub-Saharan Africa have access to it [4]. 
This study was carried out in Cameroon, a country with an HIV prevalence of 4.3%, considered as 
one of the highest in Western and Central Africa [5]. The majority of PLHIV are found in the two 
major cities of the country, which make up about 20% of the total population. In Yaoundé, 8.8% of 
women and 3.9% of men are HIV infected [6]. Access to care has considerably increased since 2007 
and reached 41% countrywide in 2010 [7]. 
One major problem related to HIV-infection, especially in Sub-Saharan Africa, is malnutrition [8]. 
HIV and undernutrition negatively affect each other in a vicious circle [9]. In particular, the deficiency 
of vitamins, minerals and antioxidants plays a critical role in the progress of HIV [10]. However, a 
review of high-dose micronutrient trials has not shown sufficient evidence to revise the WHO 
recommendation endorsing an intake at generally recommended dietary amounts [11]. The 
implementation of dietary support programs has been successful in strengthening medical care and its 
health outcomes [12–14]. Complementary to the essential role of nutrition, some aliments presented 
functional capacities with regard to immunity and detoxification. For example, a major topic for an 
efficient immune system in the case of a chronic disease burden is the sustainment of a high level  
of antioxidants [15,16]. 
The current trend for HIV and other chronic diseases is personalized nutrition [17]. Sustainable 
nutrition is based on knowledge and on the implementation of local products to cover daily dietary 
needs. Besides the nutritional aspect, aliments containing bioactive agents offer a great opportunity to 
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have an impact on the betterment of health. In particular, the rich therapeutic plant diversity in Africa 
could enhance the health of people in need [18,19]. 
In Durban in 2005, international agencies and national health departments of African States defined 
the role of nutrition in the fight against HIV in Africa. The fourth point of their statement has been one 
of the motivations for this study; “there is a proliferation in the market place of unproven diets and 
dietary therapies, with exploitation of fears, raising false hopes, and further impoverishment of those 
infected and affected by HIV and AIDS” [20]. 
Dietary interventions aiming at a delay of the progression to AIDS must focus on body weight, 
antioxidant status, viral load and/or CD4 count to describe potential changes in disease progression [21]. 
Arthrospira platensis (Asp) contains a rich diversity of bioactive molecules displaying a potential to 
improve the health of people [22–25]. Cyanobacteria are already available and considered as a safe 
dietary supplement [26]. Cell culture and animal studies with Spirulina have described antioxidant and 
antiretroviral activity, as well as an enhancement of immune defense [27–29]. Since the algae have 
been proposed to have antiretroviral activity, more research is required in order to clarify their effect 
and implementation [30,31]. 
The present study examined the effects of an intake of five grams per day of Arthrospira platensis 
focusing on the antiretroviral effect, immune function, antioxidative potential and renal function. The 
intervention added 21 kcal covering about 1% of the daily energy need. The protein supplement of the 
intervention was three grams, representing 6% of the daily protein need of women. 
2. Experimental Section 
The study was a three-month pilot, randomized, double-blind and placebo-controlled intervention. 
It was conducted according to the guidelines laid down in the Declaration of Helsinki, and all 
procedures involving human subjects were approved by ethical clearance through the ethical board of 
the faculty of medicine of Giessen University, Germany, and the national ethics committee of 
Cameroon (No. 131/CNE/SE/2010, July 16, 2010, Yaoundé). It was registered at ClinicalTrials.gov 
(NCT01084382). Informed consent was obtained from all subjects under the guidelines established. 
The study population were HIV-infected, HAART-naive women receiving outpatient care in health 
centers of Yaounde, Cameroon, between June and December, 2010. The women enrolled were not 
pregnant or breast feeding, had a BMI below 26 kg/m2 and a CD4 T-cell count of <600 CD4 
cells/mm3. The randomization into two groups was achieved chronologically for the persons recruited 
by using a randomly generated MS Excel® list dividing the participants into two groups with an equal 
number of patients. 
The product under investigation was 100% Arthrospira platensis powder provided by EARTHRISE® 
Nutritionals (Irvine, CA 92612, USA). The placebo contained the same amount of protein and energy 
using pea protein isolate Pisane F9 mixed with Dextrans (EMDEX™, HERBAMED GmbH, D-53881 
Euskirchen, Germany). The composition of both supplements are presented in Table 1. An amount of 
five grams was administered in ten pills per day with 500 mg in each tablet. This represents an 
acceptable amount of pills per day. There was no difference between the placebo and the Asp 
supplement regarding appearance and taste. The blister had an ID number without significance for the 
patient. This ID had been translated into A and B supplements for optimal handling and organization 
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of the distribution. The group attribution was cleared after the database was controlled and closed for 
analyss. The blinding was achieved by identical packaging provided by “greenValley Naturprodukte” 
GmbH (D-10997 Berlin, Germany). 
Table 1. Nutritional composition of the intervention and placebo products. 
Nutritional Composition A. platensis (500 mg) Placebo (500 mg) 
Energy 8.9 kJ/2.1 kcal 8.8 kJ/ 2.1 kcal 
Protein 310 mg 310 mg 
Carbohydrate 77.5 mg 186 mg 
Lipid 35.5 mg 4 mg 
Compliance was assessed in a monthly meeting between the patients and the physician in charge. 
The discussion was based on documentation filled in by the patients showing the number of pills and 
concomitant events for each day. The proposed concomitant events were described as: anorexia, 
fatigue, nausea/vomiting, dry or productive cough, abdominal pain, diarrhea and constipation. The 
grading was defined as “not at all”, “a little”, “as usual”, “a lot” and “enormous”. The physician filled 
in the clinical registry in which concomitant events were registered with the dates of the beginning and 
the end and the actions undertaken. 
The consultation was combined with the distribution of the supplements and the refund of the  
transportation charge. 
2.1. Marker Variables 
The blood samples were collected at the out-patient unit of the Central Hospital and brought for 
analysis to the nearby Centre Pasteur laboratory at baseline and after 12 weeks. The samples were 
collected between 10 a.m. and 12 p.m. The same materials and workflow were respected for  
all samples. 
A CD4 T lymphocyte marker was measured by way of FACS-count® (Becton, Dickinson and 
Company, Franklin Lakes, New Jersey 07417-1880, USA). 
The viral RNA was extracted from the plasma with the QIAamp® Viral RNA Mini extraction kit 
(Qiagen Inc., Chatsworth, CA, USA). The plasma viral load was run with an RT-PCR kit, known as 
Generic HIV charge Viral® (Biocentric, F- 83150 Bandol, France). All patients with an undetectable 
viral load were screened with an ELISA for the different variants of HIV-1 and HIV-2. 
The measurement of the CD38 antigen expression was performed on the Coulter® Epics XL/XL-MCL 
with the antibody combination: PE-CD3 and PE/Cy5-CD and florescent isothiocyanate, FITC-CD38, 
from (eBioscience Inc., San Diego, CA 92121, USA) 
Body weight was assessed monthly with a digital scale to the nearest 0.1 kg with the participants 
barefoot and wearing light clothes only (seca, D-22089 Hamburg, Germany). Height was measured 
with a standing board scaled to the nearest 0.5 cm. BMI (kg/m2) was calculated from weight (kg)  
and height (m). 
The antioxidant potential was measured as the total antioxidant status in blood serum (TAOS) by 
the Trolox Equivalent Antioxidant Capacity Assay kit CS790® (Sigma-Aldrich, St. Louis,  
MO 63103, USA) [32]. 
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The analyses of the renal function blood variables were performed using the system, Vitros 250®. 
The eGFR was calculated with the modification of the diet renal disease (MDRD) formula [33], 
adjusted for African women. 
2.2. Statistics 
The main objective was to determine whether the effects of a three-month supplementation of  
five grams of Arthrospira platensis were superior to a placebo regarding the course of the disease. 
The variables were described by the change occurring during the intervention with the median,  
inter-quartile range. The expected superiority of Asp over the placebo was checked by testing the null 
hypothesis. As the cohort size was around or less than 30 patients and in order to achieve a robust 
analysis, the non-parametric Mann–Whitney U-test and the Wilcoxon rank tests were applied.  
The effect magnitude of all statistic tests performed was reported by the effect size “r”.  
The correlations were achieved via the Spearman coefficient. All statistical calculations were 
performed with SPSS version 20.0 (SPSS, Chicago, IL, USA). 
3. Results 
3.1. Population 
From a screened population of 513 patients from three different health centers in Yaoundé,  
73 patients were recruited between May and July, 2010 (see Scheme 1). 
Scheme1. Participant flow in the course of the study. HAART, highly-active  
antiretroviral therapy. 
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The intervention compliance was 78%. The major reason for drop-outs during the intervention was 
the “failure to follow up”, with 50% of all drop-outs. The compliance was also affected by the health 
need of patients to start HAART. Only three patients started an antiretroviral therapy during the 
intervention, but ten of the placebo patients and two patients of the Asp groups started HAART in the 
two weeks after the intervention. The total of those starting HAART was 15 patients, which 
represented a rate of 20% of the total population and 41% of the total drop-out patients. The difference 
of those starting HAART across the groups presented a non-significantly higher proportion in the 
placebo group than in the Asp group. Furthermore, under placebo, 21 out of 30 patients (70%) 
developed one of the following concomitant events: opportunistic infections, diarrhea, headache, 
fatigue, respiratory disease or gastrointestinal symptoms. This rate was, in the Asp group, only 12 of 28 
patients (43%). The major event in both groups with a 30% incidence was malaria. Furthermore, the 
groups differed in asthenia and cephalic, with five cases in placebo and two in Asp. 
The 58 patients who enrolled and completed the intervention were unmarried, had at least a primary 
education and were of a median age of 32 (23–35) years old, showed no signs of wasting syndrome, 
had a median CD4 count of 441 (346–489) cells/mm3 and a BMI of 22 (20–23) kg/m2. The dietary 
diversity consumed over the study did not change and stayed constant for all patients at a score of four 
dietary groups per day. 
The first outcome of the intervention was a non-significantly higher proportion of patients starting 
HAART in the placebo than the Asp group, ten and five patients, respectively. There was a higher 
incidence of concomitant events, 70% in the placebo group versus 43% in the Asp group. With these 
observations, it could be useful for future studies to assess the properties of Spirulina in relation to the 
time extent from seroconversion to initiation of HAART. 
3.2. Blood Analyses 
As mentioned above, the study objective is documented by way of the CD4 T-cell count difference 
between the two products during the pilot RCT. The non-parametric comparison showed no difference 
between the groups in the variable progression over three months, r = 0.01, p = 0.926 (see Figure 1). 
Both groups presented a significant decrease: for placebo, by −52 (−111.8–−16.5) cells/mm3, r = 0.67, 
p < 0.001; and for Asp, by −66 (−111.5–−20.5) cells/mm3, r = 0.61, p < 0.001. An effect size above 0.5 
stands for a large effect, and it has to be assumed that the decrease concerns most of the involved 
patients in both groups. 
The viral load (VL) quantification method was restricted to HIV type 1 viruses. In two patients, the 
virus was undetectable. HIV-2 viral load was not systematic. However, serological tests revealed two 
patients, one in each group, with an HIV type 2 infection. The study did not test for  
double infections with HIV-1 and HIV-2. As can be expected in pre-HAART patients presenting an 
advanced infection [34], the VLs at baseline were high, with 5.5 (4.3–6) log10 corresponding to 
315,000 (20,000–1,000,000) copies/mL. The HIV-1 load did not significantly change between the two 
groups, r = 0.03, p = 0.774 (see Table 1). Inside the groups, the change could be observed on a very 
small population, as shown by the effects size, placebo r = 0.18, p = 0.329; and Asp = 0.13, p = 0.501.  
An additional three patients, two in the placebo group and one in the Asp group, presented an 
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undetectable HIV-1 viral load at the end of intervention. Those outlier patients did not report any 
antiretroviral medication or the start of HAART. 
Figure 1. The difference (Diff) of the CD4 lymphocyte counts between the groups 
receiving placebo and A. platensis at the end of the study. The box plot represents the 
median and the IQR. The zero line represents no change. The crosses indicate the means. 
 
The assessment of the immune activity through the CD38 expression on the CD8 T-lymphocyte after 
the pilot RCT did not differ between the groups, r = 0.04, p = 0.732 (see Table 2). Inside the groups, the  
T-CD8/CD38 lowered: Asp, −1.3 (−5.8%–2.0%), r = 0.24, p = 0.185; and placebo, −0.9 (−4.17%–1.56%),  
r = 0.18, p = 0.327. Furthermore, an immune activation over 40% T-CD8-CD38 present in the study 
seemed to be related to concomitant symptoms occurring during the intervention (data not shown). 
Due to the low patient numbers with concomitant symptoms, further relations could not be found. 
The TAOS trends occurring in the two groups were significantly opposite of each other, r = 0.51,  
p < 0.001 (see Table 2 and Figure 2). The TAOS increased in the Asp group by 56 (1–98) µM,  
r = 0.51, p = 0.007; whilst it decreased in the placebo group by −22 (−64–19) µM (r = 0.48,  
p = 0.008). Furthermore, in the Asp group, the TAOS increase was negatively correlated with the 
baseline (Rho = −0.436, p= 0.02). 
Both groups showed a weight increase of 0.65 (−0.30–2.50) kilograms over the three months of 
intervention: Asp, r = 0.12, p = 0.517; and placebo, r = 0.52, p = 0.005. The weight difference between 
the groups after three months was not significant: r = 0.21, p = 0.105 (see Table 2). 
The difference in serum albumin that occurred during the intervention was not significantly 
different between the groups: r = 0.07, p = 0.595. An observed slight decrease of the serum albumin 
concentrations in both groups from 49 (47–52) g/L to 47 (45–50) g/L was found statistically significant 
(placebo group, r = 0.39; p = 0.034; and Asp group, r = 0.42; p = 0.026. 
 
Arthrospira p.Placebo 
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Table 2. Study variables. TAOS, total antioxidant status in blood serum. 
Baseline Intervention Difference 
Placebo  
n = 30 
Arthrospira 
n = 28 
Placebo  
n = 30 
Arthrospira 
n = 28 
Placebo  
n = 30 
Arthrospira 
n = 28 
Variables 
Median  
(IQR) 
Median  
(IQR) 
Median  
(IQR) 
Median  
(IQR) 
Median  
(IQR) 
Median  
(IQR) 
CD4 
(Cells/mm3) 
462  
(413–558) 
440  
(415–550) 
417  
(311–486) 
406  
(320–499) 
−52  
(−112–−16) 
−66  
(−111–−20) 
Viral load 
(Log10) 
5.6  
(5.1–6) 
5.3  
(4.3–5.8) 
5.5  
(4.7–5.9) 
5.3  
(4.5–5.9) 
0.0  
(−0.4–0 0.2) 
0.05  
(−0.2–0.4) 
CD8/CD38 
(%) 
25.2  
(17.1–37.1) 
22.4  
(16.2–30.5) 
21.2  
(15.5–36.3) 
24.5  
(14.5–29.9) 
−0.9  
(−4.17–1.56) 
−1.3  
(−5.8–2.0) 
Weight (kg) 
56. 8  
(54.1–61.7) 
57.3  
(53.2–62.3) 
58.4  
(54.9–63.1) 
57.8  
(52.9–62.5) 
0.65  
(−0.1–2.9) 
0.5  
(−0.35–1.65) 
TAOS (µM) 
357  
(298–424) 
330  
(275–384) 
336  
(275–373) 
387  
(320–430) 
−22  
(−64–19) 
56  
(1–98) 
Albumin (g/L) 
49.5  
(47–52) 
49  
(47–51) 
47.5  
(46–49) 
47  
(44.5–50) 
−1.5  
(−4.0–1) 
−3.0  
(−4–0) 
Urea (g/L) 
0.19  
(0.16–0.22) 
0.17  
(0.13–0.20) 
0.18  
(0.15–0.22) 
0.18  
(0.12–0.22) 
0.00  
(−0.30–0.04) 
0.00  
(−0.35–0.03) 
Creatinine 
(mg/dL) 
0.7  
(0.6–0.8) 
0.7  
(0.6–0.7) 
0.7  
(0.6–0.8) 
0.75  
(0.6–0.85) 
0.0  
(−0.1–0.1) 
0.1  
(0.0–0.2) 
eGFR 
(mL/min) 
57.7  
(50.5–61.1) 
59.8  
(51.2–72) 
56.6  
(48.7–70.5) 
51.3  
(43–67.1) 
0.01  
(−6.7–4.6) 
−7.3  
(−17.2–0.9) 
Figure 2. TAOS difference during the RCT between placebo and Arthrospira platensis. 
The box plot represents the median and the IQR. The zero line indicates no change. The 
crosses represent the means. 
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Under the intervention with Asp, the serum creatinine rose from a baseline of 0.7 (0.6–0.7) mg/dL 
to 0.75 (0.6–0.85) mg/dL (r = 0.59, p = 0.002); whilst the placebo group did not show any change in 
serum creatinine over the intervention (r = 0.12, p = 0.51). This difference between the two groups 
after the intervention was significant, r = 0.35, p = 0.008. The concentration dependence of the eGFR 
value confirms the slight increase of serum creatinine occurring in the Asp group. The differences after 
the intervention were 0.01 (−6.73–4.62) mL/min for the placebo and −7.31 (−17.2–0.95) mL/min for 
Asp, r = 0.32; p = 0.016. The urea concentration showed no change between the groups (r = 0.13,  
p = 0.326) after the intervention. 
4. Discussion 
This randomized control trial assessed the change of relevant infection outcomes in two groups of 
female patients with preclinical HIV-infection receiving a dietary supplementation over three months. 
The intervention supplement differed from the placebo in its content of vitamins, minerals and the 
bioactive plant molecules present in Asp. 
In this study, we did not observe any benefit of an intake of five grams of Asp per day over three 
months on the viral load and/or the CD4 T-cells. The groups significantly differed on the antioxidant 
capacity and slightly in the creatinine serum levels, with increases for both outcomes in the  
Asp-supplemented group. As stated, all changes that occurred on the aforementioned markers per group 
over the intervention documented by the effect size showed a non-significant benefit for the  
Asp-supplemented group, a lower decrease for CD4 (Asp: r = 0.61, placebo: r = 0.67) and a larger 
decrease of the immune activation CD8-CD38 (Plac: r = 0.18, Asp: r = 0.24). The lack of a significant 
difference between the groups on the VL, CD4 and/or CD8-CD38 could be related to the short 
intervention duration and/or the lack of power. The Asp intervention effect on immune variables 
documented by the effect size and mentioned by the literature may relate to its rich content in 
polyphenols. A review mentioned an epigenetic mechanism of the immune modulation of polyphenol, 
which would relate an Asp action to a long-term action [35]. Furthermore, the antiretroviral effects of 
Asp described in vitro were related to the property of sulfated polysaccharide complexes with Ca2+ ions 
acting on the virus docking [27,36], but they could not be confirmed in the present human study. 
A connection between nutrition and infection is related to oxidative stress and the antioxidant  
status [37]. The measurement of the TAOS capacity is reported to provide an integrated index of 
antioxidant potential, regrouping enzyme and dietary antioxidants, as opposed to a simple summation 
of measurable antioxidants [38]. As noted in the placebo group, the TAOS decrease (r = 0.48,  
p = 0.008) reflects the progression of infection [39]. In contrast, Asp had a significantly increased 
effect on the TAOS (r = 0.51, p = 0.007). Defining the Asp effect, the significant negative correlation 
between the changes occurring during the Asp intervention and the TAOS baseline value  
(Rho = −0.436, p = 0.02) could be interpreted as a rehabilitation of patients with initially low TAOS. 
Oxidative stress can impact HIV proliferation, because the gene regulator, NF-κB, has been 
reported to enhance the gene expression of the virus [40]. The NF-κB pathway is upregulated via 
oxidative stress [40,41]. No relation between the increase of antioxidant capacity and a lowering of the 
viral particle count in the blood could be detected in this study. The viral load level of  
300,000 copies/mL is considered high and related to an acute infection progress, marking the end of 
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the latent period [34]. The high level of viral particles at baseline could mask the Asp rehabilitation 
effect on the antioxidative capacity and its impact on the viral load. 
The intervention did not aim to increase the quantity by a supplementation of 3.1 g of protein per 
day, but rather, to ameliorate the quality with all essential amino acids present in both products. The 
results have shown a similar positive impact on weight for both supplemented products. The 
significant increase for the placebo preparation would support the assumption of a stimulation of 
anabolic action by the protein content (r = 0.52, p = 0.005). The stable weight for the Asp preparation 
could be due to a functional catabolic implementation of Asp activity (r = 0.12, p = 0.517). The lack of 
a significant difference between the two products expresses the equal mixture of the Asp product and 
the placebo in terms of energy and protein gain (r = 0.21, p = 0.105). 
Furthermore, Asp was found to be associated with a significant increase of 0.1 mg/dL serum 
creatinine (r = 0.59, p = 0.002), still far below the clinically relevant mark of 1.5 mg/dL. Dietary 
protein intakes, a change in the filtration capacity of the kidneys or intense physical activity are factors 
influencing serum creatinine. The increase of the serum creatinine was also reported in a study 
supplementing 10 g of Asp daily in the Central African Republic [42], but was not associated with an 
increase of the serum urea. Therefore, it can be concluded that the additional amount of five grams of 
protein-rich supplement per day has no effect on N-metabolism. 
The outbreak of concomitant events is an indicator of the patients’ vulnerability and commonly 
indicates the need for starting HAART. As from the start patients were excluded who started HAART 
or needed relevant medication for infections and as the study patients were in the preclinical stage of 
the diseases, the rate of registered opportunistic infections was low: in the placebo group, three 
opportunistic infections occurred and there was no related exclusion. In the A. platensis group, there 
were five exclusions due to the starting of HAART and no occurrence of opportunistic infections.  
There is still a paucity of clinically controlled trials to evaluate Asp effects on humans and, 
particularly, on HIV patients. Recent studies have started to fill the gap between laboratory research 
and human application. A recent trial documented an improvement of anemia status and 
immunosenescence in healthy people after Asp supplementation [43]. An HIV-related trial has shown 
good nutritional rehabilitation effects by the consumption of Asp mixed into the rehabilitation food of 
undernourished children in Burkina Faso [44]. Another trial on HAART patients taking Asp has shown 
the amelioration of the insulin sensitivity compared to patients supplemented with soy beans [45]. One 
investigation could show that the combination of Asp and HAART resulted in a significant gain of a  
99 CD4 cells/mL count compared to a gain of 46 CD4 cells/mL for soy and HAART over a study 
period of three months [46]. 
Ingestion of A. platensis in other forms, such as enriched Asp extracts [47], or in larger amounts of 
raw powder mixed into already cooked food could be an appropriate way to enhance the beneficial 
effect of Asp for HIV-infected patients. 
Furthermore, the origin of the supplement has to be clearly defined. The culture of Asp can be 
artisanal, semi-industrial, industrial or naturally harvested. The growing condition, the quality of the 
water and correct drying are major factors influencing the safety of the product, as well as its nutrient 
content. Therefore, some results of this study may not be representative for A. platensis products 
derived from algae grown in Lake Chad or other freshwater locations. The growing conditions of the 
Nutrients 2014, 6 2983 
 
 
algae have to be considered in terms of the enrichment of the content of nutrients, e.g., calcium 
polysaccharide and lipids, as well as bioactive molecules, such as phycocyanins.  
With the non-significant observations of a difference in concomitant events and the time of 
progression of the disease resulting in the starting of HAART, it could be useful for future studies to 
also assess the properties of Spirulina regarding the time from seroconversion to the initiation of HAART. 
5. Conclusions 
In the context of the present study, Arthrospira platensis is a food rich in nutrients and bioactive 
molecules that can be grown locally. The consumption in the form of 10 capsules of dry powder, up to 
five grams a day, showed a non-significant clinical effect and no immunological activity for  
pre-HAART HIV-infected women over three months. Viral load and CD4 cell count were unaffected. 
However, the intervention seemed to reduce the incidence of concomitant events, as well as 
opportunistic infections and showed a positive effect on weight stabilization. 
Although the number of cases in this study was low, an effect of Asp on the antioxidant status could 
be documented in HAART-naive HIV patients. The use of Asp for antiretroviral activity should be 
looked at carefully, since we did not generate data supporting such an effect in the present study. 
However, Asp can be recommended as a food supplement capable of reinforcing the body’s 
antioxidative status. 
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